A two-for-one deal: both cardiovascular benefits and renal protection.
Read More »Common Diabetes Medication as Treatment for Parkinson’s Disease
Findings show Parkinson’s disease risk is reduced in patients with type 2 diabetes mellitus (T2DM) after treatment with exenatide.
Read More »Glycemic Benefit of Weekly GLP-1 Agonist: Albiglutide
Simple add-on therapy can reduce insulin use for patients with type 2 diabetes.
Read More »The Efficacy of GLP-1 Agonists in Kidney Transplant Recipients with Type 2 Diabetes
Treatment of diabetes in patients undergoing organ replacement is not often studied.
Read More »Using Pens – Keep It In and Hold It Down!
Susan received a phone call from her clinician's office recommending that she start using a pen for her insulin.
She had also been prescribed a GLP-1 receptor agonist and was to go to the pharmacy to pick them up.
She went and signed up for the long 'discourse' patients receive when they pick up new meds including questions such as whether or not the pharmacist had offered instructions and pages of small print. She, like many of our patients, signed the sheets and went on her own way without ever talking to a pharmacist or asking a question.
Weekly Semaglutide vs. Daily Sitagliptin in T2D Patients
One diabetes drug showed superior results for A1C reduction and weight loss.
Read More »The Benefits of Exenatide From the EXSCEL Study
The EXSCEL trial may not have shown that once-weekly exenatide had cardiovascular benefits for patients with diabetes, but did show a benefit in some significant areas.
Read More »Dulaglutide Can Reduce Cognitive Impairment in Patients with T2D
A recent exploratory analysis of the REWIND trial evaluated a potential additive benefit to using a once-weekly GLP-1 RA.
Read More »Old vs. New: Which T2D Agents Have the Best Renal Outcomes?
How do DPP-4 inhibitors and sulfonylureas compare to SGLT2is and GLP-1 agonists regarding renal outcomes?
Read More »Live Longer and Cardiovascular Disease-Free
How many years can semaglutide add to your life?
Read More »